Focal Segmental Glomerulosclerosis clinical trials at UCSF

• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

  open to eligible people ages 18 years and up

  The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.

  San Francisco, California and other locations

Last updated: August 3, 2021